title: A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1.
abstract: BACKGROUND
  Hyperparathyroidism (HPT) in multiple endocrine neoplasia (MEN) type 1 is associated with multiglandular parathyroid disease. Previous retrospective studies comparing subtotal parathyroidectomy (SP) and total parathyroidectomy with autotransplantation (TP/AT) have not established clearly better outcomes with either procedure.
  
  
  METHODS
  Patients were assigned randomly to either SP or TP/AT and data were collected prospectively. The rates of persistent HPT, recurrent HPT, and postoperative hypoparathyroidism were compared.
  
  
  RESULTS
  The study cohort included 32 patients randomized to receive either SP or TP/AT (mean follow-up, 7.5 ± 5.7 years). The overall rate of recurrent HPT was 19% (6/32). Recurrent HPT occurred in 4 of 17 patients (24%) treated with SP and 2 of 15 patients (13%) treated with TP/AT (P = .66). Permanent hypoparathyroidism occurred in 3 of 32 patients (9%) overall. The rate of permanent hypoparathyroidism was 12% in the SP group (2/17) and 7% in the TP/AT group (1/15). A second operation was performed in 4 of 17 patients initially treated with SP (24%), compared with 1 of 15 patients undergoing TP/AT (7%; P = .34).
  
  
  CONCLUSIONS
  This randomized trial of SP and TP/AT in patients with MEN 1 failed to show any difference in outcomes when comparing results of SP versus TP/AT. Both procedures are associated with acceptable results, but SP may have advantages in that is involves only 1 surgical incision and avoids an obligate period of transient postoperative hypoparathyroidism.
authors.affiliation: Baylor Scott and White Health Care and Texas A&M University System Health Science Center, College of Medicine, Temple, TX. Electronic address: tlairmore@sw.org.
authors.forename: Terry C
authors.initials: TC
authors.lastname: Lairmore
authors.affiliation: Baylor Scott and White Health Care and Texas A&M University System Health Science Center, College of Medicine, Temple, TX.
authors.forename: Cara M
authors.initials: CM
authors.lastname: Govednik
authors.affiliation: Baylor Scott and White Health Care and Texas A&M University System Health Science Center, College of Medicine, Temple, TX.
authors.forename: Courtney E
authors.initials: CE
authors.lastname: Quinn
authors.affiliation: Baylor Scott and White Health Care and Texas A&M University System Health Science Center, College of Medicine, Temple, TX.
authors.forename: Benjamin R
authors.initials: BR
authors.lastname: Sigmond
authors.affiliation: Baylor Scott and White Health Care and Texas A&M University System Health Science Center, College of Medicine, Temple, TX.
authors.forename: Cortney Y
authors.initials: CY
authors.lastname: Lee
authors.affiliation: Baylor Scott and White Health Care and Texas A&M University System Health Science Center, College of Medicine, Temple, TX.
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Jupiter
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications / Q000473:pathology / Q000601:surgery*; D053208:Kaplan-Meier Estimate; D008297:Male; D008991:Monitoring, Physiologic; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications / Q000473:pathology / Q000601:surgery*; D016017:Odds Ratio; D010281:Parathyroid Hormone / Q000032:analysis / Q000378:metabolism*; D016105:Parathyroidectomy / Q000379:methods*; D011182:Postoperative Care / Q000379:methods; D011446:Prospective Studies; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010281:Parathyroid Hormone